BSF Enterprise Subsidiary Receives US Patent Allowance for Serum-Free Media Technology

BSF Enterprise's subsidiary has received a Notice of Allowance from the USPTO for patent application 18/578,286, which covers proprietary serum-free media formulations using macromolecular crowding agents. This patent includes 17 claims and enhances the company's intellectual property for cell culture media used in corneal and skin cell cultivation. The development supports BSF's hub-and-spoke business strategy and is expected to reduce the high costs associated with cell culture media in biomanufacturing.